Your timeline & implications are factually incorrect & highly misleading. Both clinical & regulatory progress have advanced in a steady, coordinated path toward commercial readiness & expansion. Patients are being treated TODAY. Ironically, your daily posts & reposts only underscore that continuing progress. “Tomorrow” has arrived many times already…
Fact ✅: There was a time in recent history when NWBO had only ONE asset…
Today, NWBO has FIVE+ asset categories. Shorts are finding their position more & more precarious with each step of progress.. that’s why we see the fud flood here 24/7
Fact ✅️: Regulatory agencies may choose to consider independently peer-reviewed publications as part of their overall analysis. The MAA review is just one of several regulatory reviews to come as NWBO is developing several technologies/products. The examples below are relatively recent publications & Dr. Kalinski is currently working on another paper right now …
Fact ✅: The MHRA has already awarded several approvals, including their approval of the MIA (a prerequisite of the MAA) & their ongoing support of the DCVax-L Specials Program.
Regarding the P3, enrollment completed years before 2020, but patients continued to be treated & followed under the trial protocol as trial participants after enrollment closed. The P3 trial concluded in 2020, & data lock happened in Q4 of 2020…
COMBOS with checkpoint inhibitors & other agents are much more recent & have reached P2 for both DCVax-L & the Roswell DC technology platform.
Market Data 
Markets 
AI
